ArticleBMC pediatrics2026
Antimicrobial resistance of Group A Streptococcus isolates from patients in Shenzhen, China during COVID-19 pandemic.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGroup A Streptococcus (GAS) is a bacterial pathogen causing various infections and autoimmune diseases, with humans as its only host. Transmission occurs mainly via airborne droplets and skin mucous membrane contact. While previous surveillance studies from our group (2016–2018) established baseline resistance profiles and genotype distributions of GAS in Shenzhen, the profound societal and healthcare disruptions caused by the COVID-19 pandemic presented a unique natural experiment to investigate potential shifts in bacterial epidemiology. This study aimed to conduct a comparative molecular epidemiological analysis of GAS isolates from pediatric patients (0–18 years) in Shenzhen during the pandemic years (2019–2020), specifically focusing on temporal changes in antimicrobial resistance patterns, emm type prevalence, and Multilocus sequence types (MLST). We hypothesized that pandemic control measures might have altered GAS transmission dynamics, potentially leading to changes in the circulating strain population and its associated resistance profiles.
methodsGAS strains isolated from outpatients and wards between January 2019 and December 2020 were collected. Antimicrobial susceptibility testing was performed according to CLSI guidelines. Macrolide and tetracycline resistance genes, emm typing, and MLST were analyzed by PCR.
resultsAll 124 GAS strains were sensitive to penicillin, with 95.2% sensitive to levofloxacin. Most strains were resistant to clindamycin, azithromycin, clarithromycin, erythromycin, and tetracycline (resistance rates: 73.4%-78.2%). Chloramphenicol resistance was low (3.2%). Macrolide resistance genes were detected in 79.8% (ermB), 44.0% (ermA), and 45.1% (mefA) of strains. Tetracycline resistance genes were found in 46.7% (tetO) and 80.6% (tetM). Twelve emm types were identified, with emm1, emm3, emm4, and emm12 being common in both years. Resistance rates slightly increased in 2020 compared to 2019.
conclusionsDespite a reduction in GAS isolates collected during the pandemic, a significant increase in resistance rates to clindamycin, macrolides, and tetracycline was observed in 2020 compared to 2019 (P < 0.05). Continuous surveillance of GAS antimicrobial resistance and clonal dynamics is crucial to inform evidence-based antibiotic stewardship policies and to optimize empirical treatment strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.